The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression

Vincent Van den Eynde(PsychoTropical Research), Peter Kenneth Gillman(PsychoTropical Research), S. Ulrich, Elliott Richelson(WinnMed), Wegdan R. Abdelmoemin(University of Toronto), Stephen M. Stahl(Champalimaud Foundation), David Nutt(Imperial College London), Chittaranjan Andrade(Manipal Academy of Higher Education), Ian M. Whyte(University of Newcastle Australia), David Gotlib, Anton J.L.M. van Balkom(Vrije Universiteit Amsterdam), Jay D. Amsterdam(University of Pennsylvania), Mark D. Rego, Gordon Parker(UNSW Sydney), Bezalel Dantz(Rush University Medical Center), Boadie W. Dunlop(Emory University), Allan H. Young(King's College London), Eduard Vieta(Hospital Clínic de Barcelona), Ian Anderson(The University of Texas at Austin), Magid M. Abraham, Michael Berk(The Royal Melbourne Hospital), Ryan F. Estévez(University of Central Florida), Aartjan T.F. Beekman(Amsterdam Neuroscience), J. P. M. Finberg(Technion – Israel Institute of Technology), David B Menkes(University of Auckland), Michael E. Thase(Veterans Health Administration), Andrew Holt(University of Alberta), Glen B. Baker(Women and Children’s Health Research Institute), Tom K. Birkenhäger(Erasmus MC), Jonathan M. Meyer(Salford Royal NHS Foundation Trust), Jonathan Davidson(Duke University), C Cattaneo, Marc B.J. Blom(Parnassia Groep), Thomas G. Steele(University of South Carolina), Jens Larsen(Aarhus University Hospital), Thomas R. Insel(Stanford Health Care), Jerónimo Sáiz-Ruiz(Universidad de Alcalá), Barry Blackwell(Aurora Sinai Medical Center), Alexander J. Bodkin(Harvard University), Henricus G. Ruhé(Radboud University Nijmegen), Pierre Blier(Université du Québec à Rimouski), Shalom S. Feinberg(Albert Einstein College of Medicine), Laura J. Fochtmann(Stony Brook University)
CNS Spectrums
July 15, 2022
Cited by 72


Related Papers